Cargando…
Safety and Efficacy of s-MOX Regimen in Patients with Colorectal Cancer Who Developed Cardiotoxicity Following Fluoropyrimidine Administration: A Case Series
BACKGROUND: Fluoropyrimidines compose the backbone of regimens to treat many common solid tumors, including gastrointestinal (GI), breast and head/neck. As we continue to use these agents routinely, recognition of rare but real toxicities, such as cardiotoxicity, has also improved. The treatment opt...
Autores principales: | Ehrlich, Matthew I., Kaley, Kristin, Smith, Melissa, Saif, M. Wasif |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504879/ https://www.ncbi.nlm.nih.gov/pubmed/32964213 |
Ejemplares similares
-
Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity
por: Saif, Muhammad Wasif
Publicado: (2020) -
Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020) -
Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines
por: Shiga, Taro, et al.
Publicado: (2020) -
The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
por: Cucciniello, Linda, et al.
Publicado: (2022) -
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)